Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line

Inclusion Criteria:

Man or woman aged 18 or over;

* Patient suffering from a/mRCC, receiving sunitinib first-line treatment, as per SPC recommendations;
* Resolution (grade ≤ 1 according to CTCAE version 4.03 of June 2010) of all acute toxic effects due to radiotherapy or surgical procedure prior to initiation of sunitinib;
* Patient who can be monitored for 6 months.
* Female patient of child-bearing age using a form of contraception during treatment with Sunitinib and for at least 28 days after termination of treatment with Sunitinib;
* Patient having signed his/her consent form;
* Patient affiliated with a social security scheme.

Non-inclusion criteria

* Patient participating in a clinical trial during sunitinib treatment;
* Patient managed by a home hospitalisation service during sunitinib treatment;
* Patient taking part in therapeutic education programmes, or benefiting from nursing consultation, or from any other significant treatment support and likely to impact adverse event management.
* Patient untreated and/or symptomatic brain metastases prior to sunitinib initiation;
* Patient refusing the use of his/her personal data.
* Patient with an ECOG performance status upon inclusion \> 2;
* Patient presenting with a serum creatinine level \>1.5 times the upper limit of the normal level;
* Patient presenting with a bilirubin level \> 2 mg/dl, aspartate transaminase (ASAT) or alanine transaminase (ALAT) \>2.5 times the upper limit of the normal value, or \>5 times the upper limit of the normal value in the presence of liver metastases upon initiation of sunitinib treatment.
* Patients who are staff members of a centre involved in the study, or close to one of the staff members of a centre directly involved in conducting the study, or patients employed by Pfizer and involved in conducting the study